NCT02803918 - A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 17, 2017

Primary Completion Date

January 27, 2020

Study Completion Date

January 27, 2020

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Lixisenatide (AVE0010)

"Pharmaceutical form: solution~Route of administration: subcutaneous"

DRUG

Placebo

"Pharmaceutical form: solution~Route of administration: subcutaneous"

DRUG

Basal Insulin

"Pharmaceutical form: solution~Route of administration: subcutaneous"

DRUG

Metformin

"Pharmaceutical form: tablet~Route of administration: oral"

Trial Locations (11)

Investigational Site Number 710001, Cape Town

Investigational Site Number 840009, Philadelphia

Investigational Site Number 792001, Izmir

Investigational Site Number 484001, Monterrey

Investigational Site Number 484002, Puebla City

Investigational Site Number 840007, Lufkin

Investigational Site Number 840002, Baton Rouge

Investigational Site Number 840006, New Orleans

Investigational Site Number 480001, Phoenix

Investigational Site Number 724002, Barcelona

Investigational Site Number 792002, Ankara